Tau pathology reprograms glucose metabolism to support glutamatergic activity and excitatory imbalance

Riley E. Irmen, Sara M. Turner, James A. Snipes, Holden C. Williams, Velmurugan Gopal Viswanathan, Jerry B. Hunt, Junyan Li, Patrick G. Sullivan, Daniel C. Lee, Lance A. Johnson, Shannon L. MacauleybioRxiv 2025 · DOI

TL;DR

This study reveals that tau pathology, a hallmark of Alzheimer's disease, doesn't just disrupt brain function but actively reprograms metabolism. It preserves glucose tolerance and diurnal rhythms, shunting glucose towards glutamate production, suggesting a compensatory mechanism that may ultimately contribute to neurodegeneration by creating a metabolically inflexible, hyperexcitable state.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) and tau pathology, but also by early metabolic disruptions. While Aβ's metabolic impact is somewhat understood, how tau pathology independently affects metabolism and neuronal excitability remains unclear. This paper aims to disentangle the specific metabolic consequences of tau pathology, separate from Aβ or widespread neurodegeneration, and understand its interplay with neuronal excitability.

Methods

The researchers utilized several key techniques:

  • Mouse Models: P301S PS19 and Tau4RTg2652 mice, models of tauopathy, were used.
  • Indirect Calorimetry: To assess whole-body metabolism, including oxygen consumption (VO2), carbon dioxide production (VCO2), total energy expenditure (TEE), and respiratory exchange ratio (RER) over 72-hour periods.
  • Glucose Tolerance Tests (GTTs): To measure how efficiently mice clear glucose from their blood after a glucose bolus.
  • Intrahippocampal Biosensors: To continuously measure interstitial fluid (ISF) glucose and lactate levels in real-time, allowing for the study of diurnal rhythms and responses to challenges.
  • Stable Isotope-Resolved Metabolomics (SIRM) with GCMS: To trace the metabolic fate of 13C-labeled glucose in the brain, identifying which pathways glucose is being channeled into.
  • Bulk RNA Sequencing: To analyze gene expression changes in the cortex following glucose administration, identifying affected pathways.
  • Mitochondrial Respiration Assays (Seahorse XFe96): To measure oxygen consumption rates (OCR) in isolated synaptic and non-synaptic mitochondria.
  • Immunohistochemistry: To visualize AT8+ tau pathology in brain tissue.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Tau pathology as a metabolic "preserver": Instead of simply causing decline, tau pathology seems to actively preserve metabolic function, preventing age-related glucose intolerance and maintaining diurnal rhythms. This is a surprising counterpoint to the general understanding of neurodegenerative diseases.
  • Glucose shunted to glutamate: The brain, in the presence of tau pathology, preferentially uses glucose to synthesize glutamate, rather than for general energy production. This suggests a specific metabolic adaptation to support excitatory neurotransmission.
  • Excitatory/Inhibitory (E/I) imbalance: The shift towards glutamate production, coupled with decreased GABA, points to a significant E/I imbalance, favoring excitation. This is a critical finding for understanding how tau pathology impacts neuronal network function.
  • Time-of-day matters: The metabolic adaptations are not static; they are dynamically modulated by the circadian cycle, with different responses observed during the active (dark) and inactive (light) periods. This highlights the importance of circadian rhythms in neurodegenerative disease.
  • Metabolic inflexibility, not failure: The data suggests that the issue isn't a lack of resources but an inefficient or constrained use of them, leading to metabolic inflexibility.

Key Results

  • Cortical and Hippocampal Atrophy: P301S mice show region-specific atrophy in the cortex and hippocampus, which progresses with age, starting as early as 6 months.
  • Preserved Glucose Tolerance: P301S mice (and 4Rtg mice) do not develop age-related glucose intolerance, maintaining better glucose tolerance than age-matched WT mice.
  • Maintained Diurnal Rhythms: P301S mice preserve diurnal rhythms in hippocampal interstitial fluid (ISF) glucose and lactate, which are lost in aging WT mice.
  • Increased Glutamate Synthesis: SIRM revealed increased 13C-labeled glutamate in P301S brains, at the expense of 13C-labeled GABA.
  • Synaptic Gene Pathways Downregulated: RNA sequencing showed decreased expression of genes related to synaptic function (SynGO pathways) in P301S mice.
  • Metabolic Pathways Upregulated: Conversely, Reactome pathways related to metabolism and mitochondrial function were upregulated.
  • Intact Synaptic Mitochondria: Oxygen consumption rates in synaptic mitochondria were unchanged in P301S mice, suggesting the metabolic issues are not due to primary synaptic mitochondrial failure.
  • Glucose Fuels Glutamate: In the dark period, glucose injection led to sustained elevated ISF glutamate in P301S mice, indicating glucose is being used to support glutamatergic activity.

Limitations and Future Work

  • Causality of E/I Imbalance: The paper acknowledges that the causality between E/I imbalance and metabolic remodeling remains unresolved – is hyperexcitability causing metabolic changes, or vice versa?
  • Beneficial or Harmful Remodeling: It's unclear whether the metabolic remodeling observed is ultimately beneficial (compensatory) or harmful (contributing to neurodegeneration).
  • Longitudinal Studies & Real-time Imaging: The authors suggest that longitudinal studies, cell-type-specific interventions, and real-time metabolic imaging will be critical for disentangling these complex relationships.
  • Secondary Effects: While the study aimed to distinguish tau-driven alterations from secondary effects of neurodegeneration, this remains a challenge in the field.
  • Non-synaptic Mitochondria: A decrease in State V respiration in non-synaptic mitochondria was observed, suggesting potential subtle impairments in neuronal soma, glia, or both, which warrants further investigation.

Summary updated

Abstract

Alzheimer's disease (AD) is not only characterized by amyloid-beta (Aβ) and tau pathology, but also by early and progressive disruptions in metabolism. Neuronal excitability is tightly coupled with metabolic demand, and aberrant excitatory activity - observed in AD patients and models - can drive changes in metabolism. While Aβ-related metabolic impairments are well-described, less is known about how tau pathology independently contributes to altered metabolic states and excitatory tone. Therefore, we explored how tau pathology impacted whole body and CNS metabolism in mouse models of tauopathy, including the P301S PS19 and Tau4RTg2652 mice. In both models, hyperphosphorylated tau prevents the age-related decline in whole-body metabolism by preserving glucose tolerance and mitigating shifts in fuel utilization (respiratory exchange ratio; RER), suggesting the mice are "glucose needy". Tau pathology also preserves diurnal rhythms in hippocampal interstitial fluid (ISF) glucose and lactate, likely due to increased neuronal activity during the active (dark) phase. Stable isotope-resolved metabolomics following <sup>13</sup> C-glucose administration revealed that glucose is preferentially shunted toward glutamate synthesis-at the expense of GABA-highlighting a shift in excitatory/inhibitory balance. Interestingly, these changes were not explained by a primary deficit in synaptic mitochondria but by alterations in glycolytic flux. Adaptations were time of day dependent, where ISF glutamate rises after a glucose injection in the dark period but not the light period. This suggests increased glutamatergic activity may drive metabolic demand during the dark period when mice are more active. Together, these studies fundamentally highlight the important coupling between metabolism and excitability, which is disrupted by hyperphosphorylated tau, tau aggregation, and neurodegeneration. Understanding how tau pathology and metabolism interrelate provides a novel lens for the development of therapeutic targets in late stage AD.
BibTeX
@misc{irmen2025tau,
  author = {Riley E. Irmen and Sara M. Turner and James A. Snipes and Holden C. Williams and VELMURUGAN GOPAL VISWANATHAN and Jerry B. Hunt and Junyan Li and Patrick G. Sullivan and Daniel C. Lee and Lance A. Johnson and Shannon L. Macauley},
  title = {{Tau pathology reprograms glucose metabolism to support glutamatergic activity and excitatory imbalance}},
  year = {2025},
  doi = {10.1101/2025.07.25.666872},
  howpublished = {bioRxiv},
}
Figure